reSee.it Video Transcript AI Summary
The speakers discuss the vaccination landscape around human papillomavirus (HPV) vaccines, focusing on a controversial issue they claim has been known and disseminated since early on: contamination with DNA (DNA residuals) from Deinococcus or related genetic material in vaccines and the implications of aluminum adjuvants used in Gardasil/Gardasil 9.
- They begin by asserting that HPV vaccines, including Gardasil/Sil, have been the subject of remarkable legal actions worldwide, including four major lawsuits in Japan. They note that historically, in Japan, many young women and girls stood as plaintiffs, and that the core problem they highlight is the DNA contamination issue (referred to as “ディー エ ヌ エー 混 入 汚 染 問 題”).
- The claim is that from early on, the Japanese Ministry of Health, Labour and Welfare and others acknowledged this contamination as central. They reference a 2012 paper that reportedly made the DNA contamination problem very clear, naming pathogens such as Human Papillomavirus, HPV, and DEIN? They describe that vaccine particles (HBV? HPBL DNA fragments) were found to be directly bound to aluminum adjuvant particles in Gardasil, implying a mechanism by which residual DNA could be involved in adverse effects.
- The speakers say that the 2012 study, and subsequent work, led to attention from doctors worldwide who listened to the voices of women and girls and wondered what was happening with the vaccine recipients. They claim that samples showed that residual HPV DNA fragments were consistently present and directly linked to aluminum adjuvant particles, and that “PCR” detection indicated the same DNA sequences across samples. They mention that the 2012 paper’s findings were followed by reporting that, by 2014, vaccination had been suspended in Japan earlier than many would have expected.
- They recount a process in which major scientists from various countries (France, the UK, and others) were involved in investigating adenoviral or genetic components (they reference Shihan? and others) and that the Japan-based researchers, including Ishii Ken, were central figures. They describe meetings, PowerPoint presentations at a hotel, and a sequence of visits to the UK and the US (including HR-related planning with U.S. FDA and the UK authorities) that were interrupted by closures in the Obama era, leading to documentation and discussions about the safety concerns.
- The speakers claim that by the 2012 report and again by 2014, all vaccine samples from multiple countries contained residual DNA, and that Japan became a hub for disseminating awareness of these issues globally. They state that the issue was present not only in the early Gardasil (Gardasil-4) but also in later forms, with references to Gardasil-9 and the idea that the DNA contamination and adjuvant interactions could contribute to immune and neurological symptoms in recipients, particularly in women and girls.
- They discuss changes to WHO and FDA guidelines on residual DNA limits, noting a progression from 10 picograms to higher thresholds over time, implying corporate interests in allowing higher residual DNA quantities in vaccines. They emphasize that the shift in limits is tied to pharmaceutical companies’ needs, not human biology changes, and argue that Japan highlighted the problem of Deinance-DNA contamination during the cervical cancer vaccine era, signaling that researchers, journalists, and victims were aware long before others.
- Finally, Speaker 1 adds that two points became clear a year earlier: the disruption of messenger RNA–type vaccines as a response to safety concerns, and the subsequent rise in adverse outcomes after widespread vaccination, including deaths, which they claim intensified opposition to these vaccines.
Note: The summary presents the speakers' claims and sequencing of events as described in the transcript without evaluation or endorsement.